Prime Therapeutics Removes Two Therapies from Medicare D Formulary
Alinia and Sutent have been removed from the drug lists because of the introduction of generic therapies.
Prime Therapeutics has made several changes to its Medicare Part D formulary effective. Effective September 1, 2021, Romark Laboratories’ Alinia (nitazoxanide) tablets 500 mg and Alinia for suspension 100 mg/5mL have will no longer be covered by Medicare Part D. The change impacts several of the organization’s formularies, including Ideal Formularies and Value & Essential Formularies. Additionally, some client formularies are affected, including those of Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, and Regence.
Alinia is an anti-parasitic agent that is used to treat the symptoms of diarrhea caused by Cryptosporidium parvum or Giardia lamblia.
In March 2021, Lupin launched a generic version of nitazoxanide tablets.
Prime Therapeutics will also remove Pfizer’s Sutent (sunitinib) capsules, 12.5 mg, 25 mg, 37.5 mg, and 50 mg, from the drug list effective September 15, 2021. The change impacts several of the organization’s formularies, including Ideal Formularies and Value & Essential Formularies. Additionally, some client formularies are affected, including those of Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, and Regence.
Sutent is a chemotherapy used to treat advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys.
Prime stated that the reason for this change is that a generic is now available from Sun Pharma.
Prime Therapeutics manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid and serves more than one million Medicare beneficiaries.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
